Invention Grant
- Patent Title: Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
-
Application No.: US16219379Application Date: 2018-12-13
-
Publication No.: US10745486B2Publication Date: 2020-08-18
- Inventor: Martin Lipp , Felix Oden , Uta Höpken , Gerd Müller , Oliver Daumke , Stephen Marino , Daniel Olal
- Applicant: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
- Applicant Address: DE Berlin
- Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
- Current Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
- Current Assignee Address: DE Berlin
- Agency: Knobbe, Martens, Olson & Bear, LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@6ed10d96 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@50fc3133 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@11b08175
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/30 ; A61K39/395 ; A61K47/68 ; A61P35/00 ; A61K39/00
Abstract:
The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
Public/Granted literature
Information query
